Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 51 entries
View as:

IBCSG Trial 22-00 Serum Substudy

Phase: N/A Priority: Normal
NCT ID: NCT02393833 Org: User:
Start: 06/30/02 End: 03/06/18 Due: 03/06/19

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Phase: N/A Priority: Normal
NCT ID: NCT02046733 Org: User:
Start: 12/18/15 End: 02/01/22 Due: 02/01/23

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)

Phase: N/A Priority: Normal
NCT ID: NCT03133546 Org: User:
Start: 05/31/17 End: 02/29/24 Due: 02/28/25

Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07

Phase: N/A Priority: Normal
NCT ID: NCT01281137 Org: User:
Start: 01/31/11 End: 05/15/19 Due: 05/15/20

Premenopausal Endocrine Responsive Chemotherapy Trial

Phase: N/A Priority: Normal
NCT ID: NCT00066807 Org: User:
Start: 08/31/03 End: 12/31/06 Due: 12/31/07

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Phase: N/A Priority: Normal
NCT ID: NCT04908956 Org: User:
Start: 08/04/22 End: 02/29/24 Due: 02/28/25

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

Phase: N/A Priority: Normal
NCT ID: NCT05673187 Org: User:
Start: 06/12/23 End: 03/01/26 Due: 03/01/27

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Phase: N/A Priority: Normal
NCT ID: NCT05601973 Org: User:
Start: 03/27/23 End: 09/30/26 Due: 09/30/27

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03445000 Org: User:
Start: 11/06/18 End: 03/31/21 Due: 03/31/22

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00074152 Org: User:
Start: 07/31/02 End: 08/22/16 Due: 08/22/17

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT03762018 Org: User:
Start: 04/30/19 End: 11/18/24 Due: 11/18/25

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

Phase: N/A Priority: Normal
NCT ID: NCT00659373 Org: User:
Start: 12/31/07 End: 04/30/16 Due: 04/30/17

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

Phase: N/A Priority: Normal
NCT ID: NCT03644186 Org: User:
Start: 04/16/19 End: 04/14/23 Due: 04/14/24

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02434081 Org: User:
Start: 11/25/15 End: 03/31/20 Due: 03/31/21

Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002529 Org: User:
Start: 05/31/93 End: 08/31/10 Due: 08/31/11

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04245085 Org: User:
Start: 09/29/20 End: 07/22/24 Due: 07/22/25

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06284317 Org: User:
Start: 01/15/25 End: 03/31/30 Due: 03/31/31

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02

Phase: N/A Priority: Normal
NCT ID: NCT00963417 Org: User:
Start: 08/03/09 End: 12/31/25 Due: 12/31/26

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00066690 Org: User:
Start: 12/17/03 End: 11/06/24 Due: 11/06/25

Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004205 Org: User:
Start: 03/31/98 End: 06/30/16 Due: 06/30/17

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01562028 Org: User:
Start: 06/30/12 End: 10/31/18 Due: 10/31/19

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00296010 Org: User:
Start: 08/31/05 End: 12/31/11 Due: 12/31/12

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00022516 Org: User:
Start: 11/30/00 End: 08/31/16 Due: 08/31/17

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02536742 Org: User:
Start: 08/30/16 End: 12/22/22 Due: 12/22/23

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT02991482 Org: User:
Start: 09/12/17 End: 11/30/21 Due: 11/30/22